Out of an abundance of caution, the infant formula giant has recalled one of their powdered infant formula products because of a potentially dangerous bacteria.
On March 17, 2023, Perrigo, the world’s largest maker of over-the-counter self-care products and supplier of infant formulas for the store brand market, issued1 a voluntary recall of particular lots of their Gerber Good Start SoothePro Powdered Infant Formula in the United States.
The formula, produced at Perrigo’s Eau Claire, Wisconsin facility from January 2, 2023, to January 18, 2023, is being recalled out of an “abundance of caution,” noted an FDA press release, due to a potential presence of, an opportunistic, Gram-negative pathogenic bacterium. In infants it can cause blood infections, meningitis, and necrotizing enterocolitis.
No products that have already been distributed have tested positive for the presence of this bacteria. Additionally, no adverse events in infants have been reported at press time.
The release went on to note that anyone who purchased this product after March 5, 2023 should look for the following lot codes and “use by” dates, which can be found on the bottom of the packaging. If codes are matching, the product should be disposed of:
Gerber Good Start SootheProTM 12.4 oz:
300357651Z – USE BY 04JUL2024
300457651Z – USE BY 05JUL2024
300557651Z – USE BY 06JUL2024
300557652Z – USE BY 06JUL2024
300757651Z – USE BY 08JUL2024
300857651Z – USE BY 09JUL2024
301057651Z – USE BY 11JUL2024
301057652Z – USE BY 11JUL2024
301157651Z – USE BY 12JUL2024
Gerber Good Start SootheProTM 30.6 oz:
301357652Z – USE BY 14JUL2024
301457652Z – USE BY 15JUL2024
301557651Z – USE BY 16JUL2024
Gerber Good Start SootheProTM 19.4 oz:
301557652Z – USE BY 16JUL2024I
Noted the company in the FDA press release, “We have numerous regulatory approved procedures throughout the manufacturing process to control for Cronobacter sakazakii. Every batch of infant formula is tested to make certain it meets stringent nutritional, safety, quality, and regulatory requirements. As part of our rigorous protocols to protect the safety of families and infants, we are proactively taking this action.”
This article originally appeared in Contemporary Pediatrics.
Reference
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.